Cover Image
市場調查報告書

敗血症:開發中產品分析

Sepsis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213120
出版日期 內容資訊 英文 240 Pages
訂單完成後即時交付
價格
Back to Top
敗血症:開發中產品分析 Sepsis - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 240 Pages
簡介

所謂敗血症是細菌和其他的微生物入侵時,人體作出強烈反應的疾病。主要的症狀包含了發冷和顫抖,呼吸困難,血小板數減少,心跳功能異常,腹痛等。主要的易罹病素質有年齡和免疫疾病系的弱化等。主要的治療藥為抗生素和升壓藥等。

本報告提供全球各國治療敗血症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。 當ярみЬザゾ、世界各國ザソ敗血症治療用ソеユкьユ⑦製品ソ開發狀況ズコゆサ分析ウ、製品開發・上市ソ最新動向ビ、治驗ソ各段階ズやペ製品ソ一覽、主要企業ソк①иャユю、主ス藥劑ソ概要、最新ソ業界動向スジソ情報メれ屆んウネエ。

本報告提供全球各國治療敗血症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

敗血症概要

治療藥的開發

  • 敗血症開發中產品:概要
  • 敗血症開發中產品:比較分析

各企業開發中的敗血症治療藥

大學/研究機關研究中的敗血症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

敗血症治療藥:開發中的產品一覽(各企業)

敗血症治療藥:研究中的產品一覽(大學/研究機關)

敗血症治療藥的開發企業

  • Adrenomed AG
  • Altor BioScience Corporation
  • Am-Pharma B.V.
  • Arch Biopartners, Inc.
  • Aridis Pharmaceuticals LLC
  • 旭化成製藥
  • Astellas Pharma Inc.
  • Batu Biologics, Inc.
  • Biomedica Management Corporation
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cell2B S.A.
  • Chiesi Farmaceutici SpA
  • Chiome Bioscience, Inc.
  • Cilian AG
  • Cognosci, Inc.
  • Cytheris SA
  • Endacea, Inc.
  • Evec, Inc.
  • Huons Co., Ltd.
  • Immune Response BioPharma, Inc.
  • Immunethep, SA
  • ImmunNovative Developments SL
  • InflaRx GmbH
  • Inotrem S.A.
  • Integrated BioTherapeutics, Inc.
  • Lead Discovery Center GmbH
  • Merck & Co., Inc.
  • Navigen Pharmaceuticals, Inc.
  • OncoImmune, Inc.
  • Opsona Therapeutics Limited
  • Orion Oyj
  • ProThera Biologics, LLC.
  • Ra Pharmaceuticals, Inc.
  • Recce Pty Ltd
  • Ribomic Inc.
  • 鹽野義製藥
  • Silence Therapeutics Plc
  • SK Biopharmaceuticals Co., Ltd.
  • Stemedica Cell Technologies, Inc.
  • Syntiron LLC
  • TaiRx, Inc.
  • 武田藥品工業
  • Therakind Limited
  • Therashock, LLC
  • TiGenix NV
  • VBS Pharmaceuticals
  • ViiV Healthcare Limited
  • XImmune AB

敗血症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

敗血症治療藥:開發暫停的產品

敗血症治療藥:開發中止的產品

敗血症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8220IDB

Summary

Global Markets Direct's, 'Sepsis - Pipeline Review, H2 2016', provides an overview of the Sepsis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sepsis
  • The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects
  • The report assesses Sepsis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sepsis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sepsis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sepsis Overview
  • Therapeutics Development
    • Pipeline Products for Sepsis - Overview
    • Pipeline Products for Sepsis - Comparative Analysis
  • Sepsis - Therapeutics under Development by Companies
  • Sepsis - Therapeutics under Investigation by Universities/Institutes
  • Sepsis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Sepsis - Products under Development by Companies
  • Sepsis - Products under Investigation by Universities/Institutes
  • Sepsis - Companies Involved in Therapeutics Development
    • Adrenomed AG
    • Altor BioScience Corporation
    • Am-Pharma B.V.
    • Arch Biopartners, Inc.
    • Aridis Pharmaceuticals LLC
    • Asahi Kasei Pharma Corp.
    • Astellas Pharma Inc.
    • Batu Biologics, Inc.
    • Biomedica Management Corporation
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Cell2B S.A.
    • Chiesi Farmaceutici SpA
    • Chiome Bioscience, Inc.
    • Cilian AG
    • Cognosci, Inc.
    • Cytheris SA
    • Endacea, Inc.
    • Evec, Inc.
    • Huons Co., Ltd.
    • Immune Response BioPharma, Inc.
    • Immunethep, SA
    • ImmunNovative Developments SL
    • InflaRx GmbH
    • Inotrem S.A.
    • Integrated BioTherapeutics, Inc.
    • Lead Discovery Center GmbH
    • Merck & Co., Inc.
    • Navigen Pharmaceuticals, Inc.
    • OncoImmune, Inc.
    • Opsona Therapeutics Limited
    • Orion Oyj
    • ProThera Biologics, LLC.
    • Ra Pharmaceuticals, Inc.
    • Recce Pty Ltd
    • Ribomic Inc.
    • Shionogi & Co., Ltd.
    • Silence Therapeutics Plc
    • SK Biopharmaceuticals Co., Ltd.
    • Stemedica Cell Technologies, Inc.
    • Syntiron LLC
    • TaiRx, Inc.
    • Takeda Pharmaceutical Company Limited
    • Therakind Limited
    • Therashock, LLC
    • TiGenix NV
    • VBS Pharmaceuticals
    • ViiV Healthcare Limited
    • XImmune AB
  • Sepsis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 3K3A-APC - Drug Profile
    • 7-H9 - Drug Profile
    • AB-022 - Drug Profile
    • AcPepA - Drug Profile
    • adrecizumab - Drug Profile
    • ALT-836 - Drug Profile
    • AM/AMBP-1 - Drug Profile
    • Aspidasept - Drug Profile
    • Atu-111 - Drug Profile
    • BI-113823 - Drug Profile
    • Biologic to Inhibit PD-L1 for Immunology - Drug Profile
    • BMS-936559 - Drug Profile
    • BMS-986189 - Drug Profile
    • BRL-44408 - Drug Profile
    • BTZO-2 - Drug Profile
    • CAR Peptide - Drug Profile
    • ceftaroline fosamil - Drug Profile
    • COG-133 - Drug Profile
    • Cx-611 - Drug Profile
    • CYT-107 - Drug Profile
    • Drug for Sepsis and Septic Shock - Drug Profile
    • Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
    • Drugs to Inhibit Sialidase for Sepsis - Drug Profile
    • Escherichia coli vaccine - Drug Profile
    • ethinyl estradiol sulfonate - Drug Profile
    • EV-007156 - Drug Profile
    • Gamma-PN - Drug Profile
    • Glyco-23 - Drug Profile
    • HBN-1 - Drug Profile
    • HBN-3 - Drug Profile
    • HBN-4 - Drug Profile
    • HU-003 - Drug Profile
    • IFX-1 - Drug Profile
    • ImmStem - Drug Profile
    • ImmuneSafe - Drug Profile
    • IMT-504 - Drug Profile
    • IND-006 - Drug Profile
    • IR-999 - Drug Profile
    • Klebsiella pneumoniae vaccine - Drug Profile
    • L-257 - Drug Profile
    • L-97-1 - Drug Profile
    • L-Citrulline - Drug Profile
    • levosimendan - Drug Profile
    • M-33 - Drug Profile
    • M-6229 - Drug Profile
    • meropenem - Drug Profile
    • Metablok - Drug Profile
    • Micselon - Drug Profile
    • Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
    • Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
    • Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
    • Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile
    • Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
    • Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile
    • Motrem - Drug Profile
    • NAV-838 - Drug Profile
    • OPN-305 - Drug Profile
    • OTP-300 - Drug Profile
    • Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis - Drug Profile
    • PNV-1 - Drug Profile
    • Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile
    • RA-101295 - Drug Profile
    • RBM-005 - Drug Profile
    • RECCE-327 - Drug Profile
    • Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile
    • Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile
    • Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile
    • Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
    • Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile
    • Recombinant Protein for Inflammation and Bacterial Sepsis - Drug Profile
    • Recombinant Protein for Sepsis - Drug Profile
    • Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile
    • S-649266 - Drug Profile
    • SAN-101 - Drug Profile
    • Slit2N - Drug Profile
    • Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile
    • Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile
    • Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile
    • Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
    • Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile
    • Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile
    • Staphylococcus aureus (multivalent) vaccine - Drug Profile
    • Stem Cell Therapy for Autoimmune Diseases - Drug Profile
    • Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
    • Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile
    • Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile
    • Synthetic Peptides for Infectious Disease - Drug Profile
    • Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile
    • Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile
    • Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile
    • Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile
    • TF-0003 - Drug Profile
    • thrombomodulin alfa - Drug Profile
    • tosatoxumab - Drug Profile
    • TRX-306 - Drug Profile
    • vancomycin hydrochloride - Drug Profile
    • Yersinia pestis vaccine - Drug Profile
  • Sepsis - Dormant Projects
  • Sepsis - Discontinued Products
  • Sepsis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Sepsis, H2 2016
  • Number of Products under Development for Sepsis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Sepsis - Pipeline by Adrenomed AG, H2 2016
  • Sepsis - Pipeline by Altor BioScience Corporation, H2 2016
  • Sepsis - Pipeline by Am-Pharma B.V., H2 2016
  • Sepsis - Pipeline by Arch Biopartners, Inc., H2 2016
  • Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Sepsis - Pipeline by Asahi Kasei Pharma Corp., H2 2016
  • Sepsis - Pipeline by Astellas Pharma Inc., H2 2016
  • Sepsis - Pipeline by Batu Biologics, Inc., H2 2016
  • Sepsis - Pipeline by Biomedica Management Corporation, H2 2016
  • Sepsis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Sepsis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Sepsis - Pipeline by Cell2B S.A. , H2 2016
  • Sepsis - Pipeline by Chiesi Farmaceutici SpA, H2 2016
  • Sepsis - Pipeline by Chiome Bioscience, Inc., H2 2016
  • Sepsis - Pipeline by Cilian AG, H2 2016
  • Sepsis - Pipeline by Cognosci, Inc., H2 2016
  • Sepsis - Pipeline by Cytheris SA, H2 2016
  • Sepsis - Pipeline by Endacea, Inc., H2 2016
  • Sepsis - Pipeline by Evec, Inc., H2 2016
  • Sepsis - Pipeline by Huons Co., Ltd., H2 2016
  • Sepsis - Pipeline by Immune Response BioPharma, Inc., H2 2016
  • Sepsis - Pipeline by Immunethep, SA, H2 2016
  • Sepsis - Pipeline by ImmunNovative Developments SL, H2 2016
  • Sepsis - Pipeline by InflaRx GmbH, H2 2016
  • Sepsis - Pipeline by Inotrem S.A., H2 2016
  • Sepsis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
  • Sepsis - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Sepsis - Pipeline by Merck & Co., Inc., H2 2016
  • Sepsis - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
  • Sepsis - Pipeline by OncoImmune, Inc., H2 2016
  • Sepsis - Pipeline by Opsona Therapeutics Limited, H2 2016
  • Sepsis - Pipeline by Orion Oyj, H2 2016
  • Sepsis - Pipeline by ProThera Biologics, LLC., H2 2016
  • Sepsis - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
  • Sepsis - Pipeline by Recce Pty Ltd, H2 2016
  • Sepsis - Pipeline by Ribomic Inc., H2 2016
  • Sepsis - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Sepsis - Pipeline by Silence Therapeutics Plc, H2 2016
  • Sepsis - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Sepsis - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
  • Sepsis - Pipeline by Syntiron LLC, H2 2016
  • Sepsis - Pipeline by TaiRx, Inc., H2 2016
  • Sepsis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Sepsis - Pipeline by Therakind Limited, H2 2016
  • Sepsis - Pipeline by Therashock, LLC, H2 2016
  • Sepsis - Pipeline by TiGenix NV, H2 2016
  • Sepsis - Pipeline by VBS Pharmaceuticals, H2 2016
  • Sepsis - Pipeline by ViiV Healthcare Limited, H2 2016
  • Sepsis - Pipeline by XImmune AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Sepsis - Dormant Projects, H2 2016
  • Sepsis - Dormant Projects (Contd..1), H2 2016
  • Sepsis - Dormant Projects (Contd..2), H2 2016
  • Sepsis - Dormant Projects (Contd..3), H2 2016
  • Sepsis - Dormant Projects (Contd..4), H2 2016
  • Sepsis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Sepsis, H2 2016
  • Number of Products under Development for Sepsis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top